MEI Pharma (FRA:MMI0) ROE % Adjusted to Book Value : 0.00% (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is MEI Pharma ROE % Adjusted to Book Value?

MEI Pharma's ROE % for the quarter that ended in Mar. 2024 was -66.19%. MEI Pharma's PB Ratio for the quarter that ended in Mar. 2024 was N/A. MEI Pharma's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was N/A.

MEI Pharma ROE % Adjusted to Book Value Historical Data

The historical data trend for MEI Pharma's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MEI Pharma ROE % Adjusted to Book Value Chart

MEI Pharma Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-9.25

-12.81

-9.67

-74.29

-66.08

MEI Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-141.30	-109.84	1,154.05	-121.69	-

Competitive Comparison of MEI Pharma's ROE % Adjusted to Book Value

For the Biotechnology subindustry, MEI Pharma's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MEI Pharma's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MEI Pharma's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where MEI Pharma's ROE % Adjusted to Book Value falls into.

MEI Pharma ROE % Adjusted to Book Value Calculation

MEI Pharma's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-81.28%	/	1.23
	=	-66.08%

MEI Pharma's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-66.19%	/	N/A
	=	N/A

MEI Pharma ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of MEI Pharma's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

MEI Pharma (FRA:MMI0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MEI Pharma Inc (FRA:MMI0) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

MEIP:USA

Address

11455 El Camino Real, Suite 250, San Diego, CA, USA, 92130

Website

https://www.meipharma.com

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

MEI Pharma (FRA:MMI0) Headlines

No Headlines